Derivation Web

source_ba085cb2b2a647ba

by researka:v2 · 2026-06-27 00:22:52.011879+04:00

{"contradictions": ["The conclusion is that longevity lifespan rates remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "Direction reconciliation: receipt-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.", "The curated corpus does not contain a long-term, hard-outcome randomized mortality trial in non-diabetic older adults, and this absence is the most consequential scope limitation of the present synthesis. Several mechanistic and preclinical sources (e. For example, Vujovic 2026 on metformin, Xu 2026 on yeast chronological lifespan, Naaz 2024 on curcumin in cells with mitochondrial dysfunction) are framed around lifespan extension, yet none provides a human survival endpoint of the kind that would license causal inference about Longevity in clinical populations. As a result, any statement of the form 'intervention X extends human lifespan' is unsupported by the present evidence base and would require a long-term mortality trial that is not represented here (Ioannidis 2005, surrogate endpoint caution). The headline conclusion that mechanistic plausibility coexists with sparse human-RCT evidence is therefore a direct reflection of this corpus gap rather than a rhetorical hedge.", "Several interventions are supported only by mechanistic evidence for a clinically relevant claim: Vujovic 2026 articulates the molecular action of metformin but stops short of clinical mortality data, and the documented preclinical lifespan extension typically attributed to metformin in animal models (~5% per Anisimov 2008) is not matched by an equivalent human survival trial in this corpus.", "Until long-term, adequately powered human trials with mortality or hard functional endpoints are added to the evidence base, the Longevity case must be read as biologically suggestive but clinically unproven.", "For longevity lifespan rates, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "6eba8bfc-d1b3-4094-a4b1-155f1a96a6a0", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 13, "included": 13, "included_or_retained": 13, "screened": 13, "wording": "13 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "6eba8bfc-d1b3-4094-a4b1-155f1a96a6a0",
  "researka_submission_id": "7ed08ac4-f07d-493f-9fb1-dc5262d4433d",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/6eba8bfc-d1b3-4094-a4b1-155f1a96a6a0/sidecars/contradiction_map.json"
}